Case Report {#sec1-1}
===========

A 67-year-old Caucasian female presented to our clinic for the management of a recurrent perineal mass. Fourteen months prior, she had similar complaints and was diagnosed with superficial angiomyxoma of the perineum after surgical resection of the mass from the left paravaginal and pararectal space. The margins were negative. Immunohistochemistry of this 5×3×2.5 cm benign myxoid lesion was positive for smooth muscle actin and estrogen receptor, and negative for desmin and caldesmon. A diagnosis of superficial angiomyxoma was made ([Figure 1](#fig001){ref-type="fig"}). Two months after the procedure, she noted swelling with pain at the surgical site. A magnetic resonance imaging (MRI) of the pelvis confirmed a recurrent mass (6.4×6.2×8.5 cm) at the same site and was presumed to be a recurrent angiomyxoma. Biopsy was not obtained. The patient was started on anti-estrogen therapy with tamoxifen. She was continued on tamoxifen for a total of 8 months with very minimal resolution of her clinical symptoms. A repeated MRI revealed increasing size of the mass, for which she was switched to an aromatase inhibitor, letrozole. The patient was referred to our facility after 6 weeks of letrozole did not seem to provide any clinical or radiological benefit. The patient had a history of uterine leiomyoma for which she underwent a total abdominal hysterectomy and bilateral salpin-go-oophorectomy twenty-two years prior to this present presentation. She also had a history of vaginal dysplasia and was treated with excision sixteen years prior to presentation. At our first clinical visit, the patient complained of persistent pain in her perineal region, with noticeable discomfort in a seated position. She denied complaints with bladder or bowel habits. She denied any weight loss, fever or vaginal bleeding. A recto-vaginal examination revealed a large mass within the perineum, extending into the buttocks. MRI demonstrated a hypervascular, well circumscribed 9.8×8.1×8.8 cm ischioanal fossa tumor with considerable mass effect on adjacent structures but without invasion ([Figure 2](#fig002){ref-type="fig"}). Pelvic lymph nodes were not involved radiologically and the metastatic workup was negative.

The presumptive radiological diagnosis was recurrent angiomyxoma. She underwent embolization of the feeding vessels prior to the surgical resection, which involved a complete excision of the mass without entry into the capsule of the tumor. There was no local invasion of any surrounding structures. This was followed by a gracilis muscle flap closure of the resultant perineal defect. The resected tumor measured 11.5×10.0×9.5 cm and weighed 402 grams. Histopathology revealed a high grade spindle cell neoplasm characterized by marked cellularity and pleomorphism with increased mitotic activity (\>5 per 10 high power fields) and areas of necrosis ([Figure 3](#fig003){ref-type="fig"}). Immunohistochemistry showed positive immunoreactivity of the tumor cells for actin and desmin while S-100, CD117 and keratin AE1/AE3 were negative, confirming the diagnosis of a high grade leiomyosarcoma. The anal margin was involved by tumor. The previously excised specimen from 14 months ago was compared to the current tumor with the former demonstrating a multilobulated hypocellular tumor with circumscribed borders composed of bland stellate and spindled cells in a loose stroma with scattered thin walled vessels and sparse inflammation consistent with a diagnosis of superficial angiomyxoma ([Figure 1](#fig001){ref-type="fig"}). No atypia, increased mitotic activity or necrosis was present. She underwent adjuvant radiation therapy receiving 60 Gray in 30 fractions to the post-operative bed involving the left perineum and pelvis followed by a boost of 6 Gray in 3 fractions to the area of positive margin along the anal canal (total dose: 66 Gray in 33 fractions.) She was also offered adjuvant chemotherapy with adriamycin and ifosfamide, which she declined. She has had close follow-up clinical exams and imaging for the last 36 months, without any recurrence of her disease.

Discussion {#sec1-2}
==========

Soft tissue sarcomas are rare cancers with an annual incidence of less than 5 per 1,000,000.[@ref1] This comprises 0.7-1% of all cancers diagnosed annually, with leiomyosarcoma being one of the most common. As per the SEER data, higher incidences of leiomyosarcomas were noted in white females. Advanced grade, stage and age at diagnosis were independent markers of poor survival. The uterus and retroperitoneum were reported to be the most common anatomical sites involved.[@ref1]

Perineal leiomyosarcoma represents a very rare entity and an extensive search of the English literature reveals only a few documented case reports.[@ref2] These are aggressive tumors with no defined standard treatment protocol. Complete surgical excision is considered the treatment of choice, irrespective of the histological grade. The close proximity of these tumors to multiple vital organs often prevents complete resection with negative surgical margins. Adjuvant radiotherapy becomes imperative especially in cases with positive margins. The role of adjuvant chemotherapy is not well well-defined. Prospective clinical trials examining the use of adjuvant chemotherapy and/or radiation therapy are needed to validate their use in treatment of these rare tumors of the perineum.

The role of Positron emission tomography-computed tomography (PET-CT) scans in post-therapy surveillance to detect recurrence in asymptomatic patients with history of uterine leiomyosarcoma showed promising results.[@ref7] MRI seems to be the best diagnostic tool to characterize these lesions. Radiologically, leiomyosarcomas commonly present as soft tissue masses with low intermediate signal intensity on T 1 weighted images and high signal intensity on T2 weighted images.[@ref8]

Histologically, they are composed of highly cellular fascicles of spindle shaped cells and elongated nuclei with blunted *cigar* shaped appearance.[@ref9] Mitotic figures are generally seen throughout the lesion. The presence of high cellularity, significant nuclear atypia, necrosis, and at least 1 mitotic figure per 10 high power fields, are indicative of a malignant smooth muscle neoplasm.[@ref10] On the other hand, superficial angiomyxoma is a mesenchymal lesion with abundant mucin-rich myxoid matrix and a sparse population of stellate and spindle cells without significant atypia.[@ref11] They generally have lobular or multinodular architecture with minimal mitotic activity. Mostly curvilinear thin-walled, capillary like blood vessels are present. Mixed inflammation including presence of neutrophils may be present. These lesions are positively immunoreactive for actin and CD 34, while generally being negative for caldesmon and desmin. They may also variably express estrogen and progesterone receptors. Radiologically they can sometimes be indistinguishable from a high grade malignancy.[@ref12] Complete surgical resection remains the treatment of choice for angiomyxomas, though there is a tendency for local recurrence.[@ref11] There has been some benefit with anti-estrogen therapy used as definitive treatment for primary and recurrent aggressive angiomyxomas.^[@ref13],[@ref14]^ They have also been used in the neo-adjuvant setting to reduce tumor volume especially for those arising in difficult locations where surgical resection remains a challenge.[@ref15] Use of hormonal agents has also been tried in the adjuvant setting after resection of the primary or recurrent angiomyxoma.[@ref16] Both the Gonadotropin-releasing hormone analogs and the aromatase inhibitors have been used, with the choice of agent depending on the menopausal status of the patient.[@ref17] However, these treatment choices have not yet been studied prospectively and most cases have a history of aggressive angiomyxomas and not superficial angiomyxoma. Thus, a prompt histological diagnosis of any such presumed recurrent angiomyxoma becomes imperative. More recently, analysis of microRNA expression profiling and the discovery of high frequency of *Pten* mutations and its role in genomic instability have been described in leiomyosarcomas.^[@ref18],[@ref19]^ Molecular and proteomic analysis along with screening for alterations in *Pten* genes, will now provide us with an opportunity to improve the classification of soft tissue tumors, better predict the outcomes and personalize therapy with the help of specific small molecular inhibitors and other targeted therapies.[@ref20] Several clinical trials are underway to answer these questions. This might be beneficial in our patient in the future, in case of local or distant recurrence. No such mutational analysis has been studied in benign superficial angiomyxomas. It is highly unlikely that these two histologically distinct tumors have a similar cell of origin.

Conclusions {#sec1-3}
===========

To the best of our knowledge, this is the first reported case of a high grade perineal leiomyosarcoma originating at the same site of a resected benign superficial angiomyxoma. Our case also emphasizes the necessity of a prompt histological diagnosis in cases of presumed recurrent perineal angiomyxomas. It also challenges the role of any adjuvant chemotherapy in cases of leiomyosarcoma.

![Multilobulated hypocellular tumor (angiomyxoma) with circumscribed borders composed of bland stellate and spindled cells in a loose stroma with scattered thin walled vessels and sparse inflammation (Hematoxylin & Eosin, ×2). Inset: Hematoxylin & Eosin, ×20.](rt-2015-2-5875-g001){#fig001}

![Magnetic resonance imaging scan demonstrating a hypervascular, well circumscribed 9.8×8.1×8.8 cm ischioanal fossa tumor with considerable mass effect on adjacent structures but without invasion.](rt-2015-2-5875-g002){#fig002}

![High grade spindle cell neoplasm (leiomyosarcoma) with marked cellularity and pleomorphism with increased mitotic activity and areas of necrosis present elsewhere in the tumor (Hematoxylin & Eosin, ×20).](rt-2015-2-5875-g003){#fig003}
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